Biogen's SWOT analysis: neurology giant faces pipeline hurdles, stock outlook mixed
Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...
American Association of Individual Investors1d
Which Is a Better Investment, Biogen Inc. or Natera, Inc. Stock?
Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Exchange Traded Concepts LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB)
Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...
pharmaphorum1d
Four ways Biogen is tackling digital innovation in neurological disease
One example of a patient-facing app in Biogen’s portfolio is Cleo, an app for MS patients which the group launched in 2018. “An MS patient would typically meet their neurologist only twice a ...
pharmaphorum4d
Dangerous inflammation prompts worldwide withdrawal of MS drug
Biogen and AbbVie have announced the voluntary ... This includes those who experience highly active relapsing MS despite having undergone a full and adequate course of treatment with at least ...
The Armenian Reporter2h
Hunter Associates Investment Management LLC Decreases Stake in Biogen Inc. (NASDAQ:BIIB)
Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...
lifesciencesipreview3d
Dutch court axes Biogen’s MS patent, clearing way for generics
Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...